These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX. Tanaka M, Heckler M, Mihaljevic AL, Sun H, Klaiber U, Heger U, Büchler MW, Hackert T. Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446 [Abstract] [Full Text] [Related]
5. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. Sehdev A, Gbolahan O, Hancock BA, Stanley M, Shahda S, Wan J, Wu HH, Radovich M, O'Neil BH. Clin Cancer Res; 2018 Dec 15; 24(24):6204-6211. PubMed ID: 30131383 [Abstract] [Full Text] [Related]
6. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. Hohla F, Hopfinger G, Romeder F, Rinnerthaler G, Bezan A, Stättner S, Hauser-Kronberger C, Ulmer H, Greil R. Int J Oncol; 2014 Jan 15; 44(1):319-26. PubMed ID: 24247204 [Abstract] [Full Text] [Related]
7. A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FOLFIRINOX chemotherapy. van Eijck CWF, Sabroso-Lasa S, Strijk GJ, Mustafa DAM, Fellah A, Koerkamp BG, Malats N, van Eijck CHJ. Neoplasia; 2024 Mar 15; 49():100975. PubMed ID: 38335839 [Abstract] [Full Text] [Related]
10. Identification of a six-miRNA panel in serum benefiting pancreatic cancer diagnosis. Zou X, Wei J, Huang Z, Zhou X, Lu Z, Zhu W, Miao Y. Cancer Med; 2019 Jun 15; 8(6):2810-2822. PubMed ID: 31006985 [Abstract] [Full Text] [Related]
11. Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis. Zhou X, Lu Z, Wang T, Huang Z, Zhu W, Miao Y. Gene; 2018 Oct 05; 673():181-193. PubMed ID: 29913239 [Abstract] [Full Text] [Related]
14. Serum miR-338-3p and miR-199b-5p are associated with the absolute neutrophil count in patients with resectable pancreatic cancer. van der Sijde F, Vietsch EE, Mustafa DAM, Li Y, van Eijck CHJ. Clin Chim Acta; 2020 Jun 05; 505():183-189. PubMed ID: 32145274 [Abstract] [Full Text] [Related]
15. Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia. Vila-Navarro E, Duran-Sanchon S, Vila-Casadesús M, Moreira L, Ginès À, Cuatrecasas M, Lozano JJ, Bujanda L, Castells A, Gironella M. Clin Transl Gastroenterol; 2019 Apr 05; 10(4):e00029. PubMed ID: 31009404 [Abstract] [Full Text] [Related]
17. Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer. Wei T, Zhang Q, Li X, Su W, Li G, Ma T, Gao S, Lou J, Que R, Zheng L, Bai X, Liang T. Mol Cancer Ther; 2019 Jan 05; 18(1):196-203. PubMed ID: 30301865 [Abstract] [Full Text] [Related]
18. Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer. Hussein NA, Kholy ZA, Anwar MM, Ahmad MA, Ahmad SM. J Cancer Res Clin Oncol; 2017 Jan 05; 143(1):83-93. PubMed ID: 27631726 [Abstract] [Full Text] [Related]